BioCentury reported an accelerating loss of FDA staff and experience, a trend that biopharma CEOs, investors and patient advocates warn is degrading regulatory oversight and making drug development slower and less predictable. The article detailed recruiter surveys and stakeholder interviews pointing to gaps in institutional expertise across program review teams. Industry sources said departures complicate regulatory interactions and increase uncertainty for sponsors preparing filings or seeking timely advice. The story cited concerns that a shrinking workforce may impair review quality, responsiveness and the agency’s ability to manage complex scientific evaluations. Companies and trade groups are now lobbying for retention measures and workforce rebuilding to restore predictability in regulatory pathways and preserve review capacity for emerging modalities.